High -Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
This study uses a sequence of high-dose chemotherapy drugs and a stem cell transplant to treat multiple myeloma. The study is being performed to evaluate the efficacy and side effects of treatment. Specifically, the study is designed to reduce the risk of interstitial pneumonitis.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : cyclophosphamide
- drug : BCNU Melphalan
- drug : etoposide
Phase: Phase 1/Phase 2
Ages Eligible For Study:
- Multiple myeloma. Eligible patients may have early or relapsed disease. Patients must have Stage II-III disease or have progression after initial treatment of Stage I disease. - Age 18-75 years. - Patients must have their pathology reviewed and the diagnosis confirmed at Stanford University Medical Center. Patients with smoldering multiple myeloma, monoclonal gammopathy of unknown significance, or primary amyloidosis will be excluded from this study. Patients with multiple myeloma and amyloidosis may be eligible for this trial, with approval by the Principle Investigator. - Patients must have a Karnofsky performance status > 70%. - DLCO >=60% predicted. - ALT and AST must be < 2X normal. Total bilirubin less than 2 mg/dl. - Serum creatinine < 2.0 or 24-hour creatinine clearance e 60 ml/min. - Patients must be HIV negative. - Pregnant or lactating women will not be eligible to participate. - Patients must provide signed, informed consent.